• Publications
  • Influence
Effects of 5,6-dimethylxanthenone-4-acetic acid on human tumor microcirculation assessed by dynamic contrast-enhanced magnetic resonance imaging.
TLDR
DMXAA significantly reduces DCE-MRI parameters related to tumor blood flow, over a wide dose range, consistent with the reported tumor vascular targeting activity. Expand
Standard-dose pembrolizumab in combination with reduced-dose ipilimumab for patients with advanced melanoma (KEYNOTE-029): an open-label, phase 1b trial.
TLDR
Data suggest that standard-dose pembrolizumab plus reduced-dose ipilimumab might be a tolerable, efficacious, and robust anti-tumour activity in patients with advanced melanoma. Expand
Induction of endothelial cell apoptosis by the antivascular agent 5,6-dimethylxanthenone-4-acetic acid
TLDR
It is concluded that 5,6-Dimethylxanthenone-4-acetic acid can induce vascular endothelial cell apoptosis in some murine and human tumours and appears to be independent of tumour necrosis factor induction. Expand
Clinical aspects of a phase I trial of 5,6-dimethylxanthenone-4-acetic acid (DMXAA), a novel antivascular agent
TLDR
DMXAA was well tolerated at lower doses and no drug-related myelosuppression was seen, and Rapidly reversible dose-limiting toxicities were observed at 4900 mg m−2, including confusion, tremor, slurred speech, visual disturbance, anxiety, urinary incontinence and possible left ventricular failure. Expand
5,6-Dimethylxanthenone-4-Acetic Acid in the Treatment of Refractory Tumors: a Phase I Safety Study of a Vascular Disrupting Agent
TLDR
Doses in the range of 1,200 mg m−2 have been selected for further studies because this dose produced no significant effect on heart rate–corrected cardiac QT interval, produced near maximum levels of 5-hydroxyindoleacetic acid, achieved DMXAA plasma concentrations within the preclinical therapeutic range, and was well tolerated. Expand
Randomised phase II study of ASA404 combined with carboplatin and paclitaxel in previously untreated advanced non-small cell lung cancer
TLDR
The feasibility of combining ASA404 with carboplatin and paclitaxel in patients with previously untreated, advanced NSCLC is established, demonstrating a manageable safety profile and lack of adverse pharmacokinetic interactions. Expand
A phase I trial of PR-104, a nitrogen mustard prodrug activated by both hypoxia and aldo-keto reductase 1C3, in patients with solid tumors
TLDR
PR-104 was well tolerated at a dose of 1,100 mg/m2 administered as an IV infusion every 3 weeks and the area under the PR-104A plasma concentration–time curve at this dose exceeded that required for activity in human tumor cell cultures and xenograft models. Expand
A phase I trial of PR-104, a pre-prodrug of the bioreductive prodrug PR-104A, given weekly to solid tumour patients
TLDR
PR-104 given weekly may be a suitable protocol for further clinical evaluation as a short course of treatment with fractionated radiotherapy or haematopoietic stem cell support, as its duration of dosing is restricted by delayed-onset and protracted thrombocytopenia. Expand
A Phase 1 Study of AS1409, a Novel Antibody-Cytokine Fusion Protein, in Patients with Malignant Melanoma or Renal Cell Carcinoma
TLDR
The maximum tolerated dose was established at 15 μg/kg weekly and evidence of efficacy assessed by RECIST, functional imaging, and biomarker response warrants the planned further investigation using this dose and schedule in malignant melanoma. Expand
Review of high‐dose intravenous vitamin C as an anticancer agent
TLDR
Current clinical evidence for a therapeutic effect of high‐dose IV vitamin C is ambiguous, being based on case series, and the interpretation and validation of these studies is hindered by limited correlation of plasma vitamin C concentrations with response. Expand
...
1
2
3
4
5
...